Drugs / AAV9 Vector Expressing Human ß-galactosidase
AAV9 Vector Expressing Human ß-galactosidase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07479953 | Jun 2026 → Jun 2038 expected | GM1 gangliosidosis type 1, GM1 gangliosidosis type 2 | Tippi Mackenzie | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV9 Vector Expressing Human ß-galactosidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07479953 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV9 Vector” NCT07479953 ↗ |
| Route | Intravenous | “Prenatal Intravenous Gene Transfer” NCT07479953 ↗ |